drugset
drugset / Trial / NCT00414180

Bupropion SR for Treating Smokeless Tobacco Use

NCT00414180 ↗

Phase 3 Completed 225 enrolled Mayo Clinic West Virginia University · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the efficacy and safety of bupropion SR for quitting tobacco in smokeless tobacco users.

Timeline

Start
2003-08
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg —

Indications

No indication recorded.